These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34771640)

  • 1. Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review.
    Freitas AJA; Causin RL; Varuzza MB; Hidalgo Filho CMT; Silva VDD; Souza CP; Marques MMC
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy.
    Chou HH; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Yu MC; Lo YF; Dabora MA; Chang HK; Lin YC; Ueng SH; Chen SC
    Biomed J; 2019 Feb; 42(1):66-74. PubMed ID: 30987708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
    Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer.
    Özgür E; Ferhatoğlu F; Şen F; Saip P; Gezer U
    Cancer Biomark; 2020; 27(1):11-17. PubMed ID: 31640083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
    Alves WEFM; Bonatelli M; Dufloth R; Kerr LM; Carrara GFA; da Costa RFA; Scapulatempo-Neto C; Tiezzi D; da Costa Vieira RA; Pinheiro C
    BMC Cancer; 2019 Dec; 19(1):1173. PubMed ID: 31795962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The history, present situation, and future directions of neoadjuvant chemotherapy for HER2-negative breast cancer.
    Oikawa M
    Chin Clin Oncol; 2020 Jun; 9(3):29. PubMed ID: 32576021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.
    Cabrera-Galeana P; Muñoz-Montaño W; Lara-Medina F; Alvarado-Miranda A; Pérez-Sánchez V; Villarreal-Garza C; Quintero RM; Porras-Reyes F; Bargallo-Rocha E; Del Carmen I; Mohar A; Arrieta O
    Oncologist; 2018 Jun; 23(6):670-678. PubMed ID: 29490940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
    Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N
    Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study.
    Zeidman M; Alberty-Oller JJ; Ru M; Pisapati KV; Moshier E; Ahn S; Mazumdar M; Port E; Schmidt H
    Breast Cancer Res Treat; 2020 Nov; 184(1):203-212. PubMed ID: 32740807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
    Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
    Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
    Orsaria P; Grasso A; Ippolito E; Pantano F; Sammarra M; Altomare C; Cagli B; Costa F; Perrone G; Soponaru G; Caggiati L; Vanni G; Buonomo OC; Altomare V
    Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in use of neoadjuvant chemotherapy in patients with stage III breast cancer: Results of the Dutch national breast cancer audit.
    Spronk PER; van Bommel ACM; Siesling S; Wouters MWJM; Vrancken Peeters MTFD; Smorenburg CH
    Breast; 2017 Dec; 36():34-38. PubMed ID: 28942098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
    Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
    Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: The Relationship Between Inflammatory Biomarkers and Molecular Subtypes.
    Kaytaz Tekyol K; Gurleyik G; Aktaş A; Aker F; Tanrikulu E; Tekyol D
    Cureus; 2021 Apr; 13(4):e14774. PubMed ID: 34094739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.
    Dong J; Sun Q; Pan Y; Lu N; Han X; Zhou Q
    BMC Cancer; 2021 Jun; 21(1):700. PubMed ID: 34126950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.